Broker Morgans doesn’t have a formal coverage on NEU, but biotech analyst Scott Power believes that Neuren has a deep pipeline that could produce more positive results down the line.“The company has been around for quite a long time, like 20 years, and they’ve had various ups and downs,” Power told *.“But this result is very important for them and was an inflection point, and I agree when they said it would only be the starting line.”
Pilcher said the NEU stock price has been severely undervalued for a long time, because people had major doubts whether the company would be able to get positive results from the clinical trials.
“We’ve got three analysts covering the stock, and I’m confident that with the latest results, they’re going to update their models and come up with a valuation well north of where the share price is right now.”
-
- There are more pages in this discussion • 1,517 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$16.48 |
Change
-0.290(1.73%) |
Mkt cap ! $2.076B | |||
| Open | High | Low | Value | Volume |
| $16.58 | $16.74 | $16.40 | $9.107M | 549.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 864 | $16.43 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $16.50 | 1668 | 1 |
View Market Depth
| Last trade - 16.10pm 25/07/2025 (20 minute delay) ? |
| NEU (ASX) Chart |